Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 13, 2026Advances in TherapyOpen Access

Indirect Comparison of the Efficacy of Zanubrutinib vs Ibrutinib and Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-Up

View Full Paper
Ask AI
Bookmark
Share

Authors

MSMazyar ShadmanTMTalha MunirSXSheng Xu

Discussion

Loading...

Member takes

Overview

Randomized trial compares the efficacy of zanubrutinib, ibrutinib, and acalabrutinib in treatment-naive CLL, suggesting benefits of zanubrutinib.

Key Points

  • This analysis aimed to compare the efficacy of zanubrutinib, ibrutinib, and acalabrutinib in treatment-naive chronic lymphocytic leukemia.
  • Conducted indirect comparisons of zanubrutinib vs ibrutinib and zanubrutinib vs acalabrutinib using data from phase 3 trials, SEQUOIA, ELEVATE-TN, and RESONATE-2.
  • Eligibility criteria were aligned for cross-trial comparability, focusing on treatment-naive CLL patients without del(17p) and/or TP53 mutations.
  • Included median follow-up periods of 73.4 months for zanubrutinib vs ibrutinib and 73.6 months for zanubrutinib vs acalabrutinib.
  • Zanubrutinib significantly prolonged PFS-INV (HR 0.65, 95% CI 0.44-0.97, P=0.0330) and showed a trend toward improved OS (HR 0.60, 95% CI 0.36-1.01, P=0.0532) compared to ibrutinib.
  • At 72 months, PFS-INV rates were significantly higher with zanubrutinib vs ibrutinib (risk difference 15.3%, 95% CI 8.3-22.2%).
  • Compared to acalabrutinib, zanubrutinib trended toward improved PFS-INV (HR 0.76, 95% CI 0.52-1.11, P=0.1553) and OS (HR 0.66, 95% CI 0.41-1.06, P=0.0836).

Cite This Study

Shadman et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf62dfaef96ed7f05800ehttps://doi.org/10.1007/s12325-026-03661-w
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world comparative effectiveness of first-line BTK inhibitors in chronic lymphocytic leukemia2026
  2. 2Adverse event profiles of acalabrutinib and zanubrutinib in chronic lymphocytic leukemia: A real-world comparison2025 · 1 citations
  3. 3Comparative efficacy of Bruton tyrosine kinase inhibitors in the treatment of relapsed/refractory chronic lymphocytic leukemia: A network meta-analysis (NMA).2024 · 3 citations
  4. 4Prolonged progression-free survival with zanubrutinib in relapsed/refractory CLL: an indirect treatment comparison versus other BTK inhibitors using multilevel network meta-regression2026
  5. 5Indirect comparison of efficacy of zanubrutinib vs ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma2025 · 1 citations